Smart + Strong.
All Rights Reserved.
Smart + Strong®
is a registered trademark of CDM Publishing, LLC.
Molnupiravir, the first oral antiviral for COVID-19, reduces the risk of hospitalization or death if started within five days.
Post-exposure and pre-exposure prophylaxis could be a game-changer for immunocompromised people.
Certain racial/ethnic groups and older people aren’t being adequately represented and trial reporting guidelines aren’t being followed.
The study asks whether certain approved therapies or late-stage investigational drugs show promise against COVID-19.
The trial is evaluating an investigational vaccine from Janssen that may require only one shot.
You have been inactive for 60 minutes and will be logged out in . Any updates not saved will be lost.
Click here to log back in.